Glimepiride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Glimepiride |
| DrugBank ID | DB00222 |
| Brand Names (EU) | Glimepiride |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.77% |
Approved Indication (EMA)
Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | diabetes mellitus (disease) | 99.77% | DL |
| 2 | classic stiff person syndrome | 99.75% | DL |
| 3 | focal stiff limb syndrome | 99.75% | DL |
| 4 | opsismodysplasia | 99.74% | DL |
| 5 | thiamine-responsive dysfunction syndrome | 99.73% | DL |
| 6 | drug-induced localized lipodystrophy | 99.62% | DL |
| 7 | centrifugal lipodystrophy | 99.60% | DL |
| 8 | pressure-induced localized lipoatrophy | 99.59% | DL |
| 9 | idiopathic localized lipodystrophy | 99.56% | DL |
| 10 | pancreatic agenesis | 99.55% | DL |
| 11 | type 1 diabetes mellitus | 98.86% | DL |
| 12 | autoimmune oophoritis | 98.80% | DL |
| 13 | diabetes mellitus, insulin-dependent, X-linked, susceptibility to | 92.43% | DL |
| 14 | homozygous familial hypercholesterolemia | 92.26% | DL |
| 15 | permanent neonatal diabetes mellitus | 82.39% | DL |
| 16 | type 2 diabetes mellitus | 79.07% | DL |
| 17 | IDDM 1 | 77.93% | DL |
| 18 | hypotrichosis simplex of the scalp | 71.43% | DL |
| 19 | congenital hypotrichosis milia | 64.99% | DL |
| 20 | cholangiocarcinoma, susceptibility to | 63.33% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.